AstraZeneca will use Regeneron's VelocImmune technology to discover human monoclonal antibodies. It will do the research work at Cambridge Antibody Technology, a British company AstraZeneca acquired last year. ...
Under the terms of the agreement, AstraZeneca will pay Regeneron $20 million upfront and make up to five annual payments of $20 million. It will also pay Regeneron a royalty in the mid-single digits on any products that come to market.
Monday, February 12, 2007
Antibody Deal
AstraZeneca & Regeneron:
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment